PCSK9 and cardiovascular disorder: Here, we show that PCSK9 inhibition with bococizumab resulted in highly selective reduction of PCSK9 plasma levels without affecting over 30 well-known inflammatory proteins in the Olink panels, implying PCSK9 inhibition lowers atherosclerotic cardiovascular disease risk via pure lipid-lowering pathways.